文献速递技术与安全乳腺CT

驱动同一患者不同转移灶治疗反应异质性的因素:基于RECIST 1.1分析

Factors That Drive Heterogeneity of Response-to-Treatment of Different Metastatic Deposits Within the Same Patients as Measured by RECIST 1.1 Analyses.
PubMed 文献 · Acad Radiol · 2020-06-30

研究用三名放射科医师在RECIST 1.1下阅片者间变异率作为指标,前瞻性评估355例不同原发肿瘤转移患者中200例靶病灶选择不同者的治疗反应异质性。200例中67例(34%)存在异质性治疗反应,乳腺癌是唯一与异质性风险统计学显著升高相关的原发肿瘤(OR 3.972,95%CI 1.275-12.376,p=0.017),全身治疗类型与异质性无关。

要点

  • 约三分之一转移性疾病患者在RECIST 1.1评估中可出现临床显著的治疗反应异质性
  • 乳腺癌转移患者出现治疗反应异质性的风险高于其他原发肿瘤(OR 3.972)
  • 全身治疗类型与转移灶治疗反应异质性的出现无关联

核心结论

  • 临床显著的治疗反应异质性在当代全身治疗患者中常见,约三分之一患者存在;乳腺癌患者更可能出现这种异质性;全身治疗类型不调节转移灶治疗反应分歧的可能性。

研究设计与样本

  • 前瞻性研究,355例不同原发肿瘤的转移性疾病患者于2015年7月至2017年12月接受增强CT检查,三名放射科医师独立使用专用肿瘤疗效评估软件(MintLesion)按RECIST 1.1判定治疗反应;其中200例因阅片者选择不同靶病灶组而纳入进一步分析。

诊断标准与关键数值

  • 以RECIST 1.1结果在进展与非进展疾病区分上不一致定义为存在临床显著的治疗反应异质性;200例中67例(34%)观察到异质性治疗反应;乳腺癌是唯一与治疗反应异质性风险统计学显著升高相关的原发肿瘤(OR 3.972,95%CI 1.275-12.376,p=0.017);全身治疗类型与生物学异质性率无关联。

临床应用与阅片要点

  • 日常阅片按RECIST 1.1评估转移性疾病时需注意同一患者不同转移灶间可能出现治疗反应分歧。
  • 乳腺癌转移患者出现治疗反应异质性的可能性较高,阅片和报告时应留意靶病灶选择对疗效判定的影响。
  • 全身治疗类型不改变出现转移灶治疗反应分歧的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVE: This study uses the rate of between-reader variability under Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 as a metric to estimate the prevalence of biologic heterogeneity of individual metastases, and to determine whether this prevalence is modulated by the type of primary tumor, or type of treatment administered.

MATERIALS AND METHODS: Three radiologists independently used dedicated oncologic response-assessment software (MintLesion) to prospectively determine RECIST1.1 treatment response in contrast-enhanced computed tomography studies of 355 patients with metastatic disease of different primaries between 07/2015 and 12/2017. In 200 patients, readers had chosen different sets of target lesions; these cases were used for further analysis. Clinically significant heterogeneity of response was considered to be present when RECIST1.1 results differed regarding the distinction of progressive versus non-progressive disease. Rates of response heterogeneity were compared for different types of primary cancers, and different types of systemic treatment.

RESULTS: Heterogeneous treatment response was observed in 67 of 200 (34%) patients. Breast cancer was the only primary tumor associated with statistically significantly increased odds for heterogeneity of treatment response (Odds Ratio: 3.972, 0.95 Confidence Interval: 1.275-12.376, p = 0.017). No association was found between type of systemic treatment and rate of biologic heterogeneity.

CONCLUSION: Clinically significant heterogeneity of response-to-treatment is a frequent phenomenon, observed in about one-third of patients undergoing contemporary systemic therapies. Patients with breast cancer are more likely to exhibit such heterogeneity. Type of systemic treatment did not modulate the likelihood of exhibiting metastases with diverging treatment response.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zimmermann M, Kuhl CK, Engelke H, et al. Factors That Drive Heterogeneity of Response-to-Treatment of Different Metastatic Deposits Within the Same Patients as Measured by RECIST 1.1 Analyses. Acad Radiol. 2020. PMID: 32616417. doi:10.1016/j.acra.2020.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。